These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27649927)

  • 1. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.
    Kushner BH; Cheung NV; Modak S; Becher OJ; Basu EM; Roberts SS; Kramer K; Dunkel IJ
    Int J Cancer; 2017 Jan; 140(2):480-484. PubMed ID: 27649927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma.
    Matsumoto K; Shichino H; Kawamoto H; Kosaka Y; Chin M; Kato K; Mugishima H
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28521076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine.
    Li Z; Tan F; Liewehr DJ; Steinberg SM; Thiele CJ
    J Natl Cancer Inst; 2010 Jun; 102(11):758-70. PubMed ID: 20463309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.
    Becher OJ; Millard NE; Modak S; Kushner BH; Haque S; Spasojevic I; Trippett TM; Gilheeney SW; Khakoo Y; Lyden DC; De Braganca KC; Kolesar JM; Huse JT; Kramer K; Cheung NV; Dunkel IJ
    PLoS One; 2017; 12(6):e0178593. PubMed ID: 28582410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo.
    Li Z; Oh DY; Nakamura K; Thiele CJ
    Cancer; 2011 Dec; 117(23):5412-22. PubMed ID: 21590687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
    Argiris A; Cohen E; Karrison T; Esparaz B; Mauer A; Ansari R; Wong S; Lu Y; Pins M; Dancey J; Vokes E
    Cancer Biol Ther; 2006 Jul; 5(7):766-70. PubMed ID: 16760642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
    Durbas M; Horwacik I; Boratyn E; Kamycka E; Rokita H
    Int J Oncol; 2015 Sep; 47(3):1143-59. PubMed ID: 26134970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
    Kaley TJ; Panageas KS; Mellinghoff IK; Nolan C; Gavrilovic IT; DeAngelis LM; Abrey LE; Holland EC; Lassman AB
    J Neurooncol; 2019 Sep; 144(2):403-407. PubMed ID: 31325145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma.
    Smith JR; Moreno L; Heaton SP; Chesler L; Pearson AD; Garrett MD
    Mol Oncol; 2016 Apr; 10(4):538-52. PubMed ID: 26686971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
    Ghobrial IM; Roccaro A; Hong F; Weller E; Rubin N; Leduc R; Rourke M; Chuma S; Sacco A; Jia X; Azab F; Azab AK; Rodig S; Warren D; Harris B; Varticovski L; Sportelli P; Leleu X; Anderson KC; Richardson PG
    Clin Cancer Res; 2010 Feb; 16(3):1033-41. PubMed ID: 20103671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/TrkB signal transduction pathway.
    Li Z; Thiele CJ
    Expert Opin Ther Targets; 2007 Dec; 11(12):1611-21. PubMed ID: 18020981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
    Papa V; Tazzari PL; Chiarini F; Cappellini A; Ricci F; Billi AM; Evangelisti C; Ottaviani E; Martinelli G; Testoni N; McCubrey JA; Martelli AM
    Leukemia; 2008 Jan; 22(1):147-60. PubMed ID: 17928881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
    Becher OJ; Gilheeney SW; Khakoo Y; Lyden DC; Haque S; De Braganca KC; Kolesar JM; Huse JT; Modak S; Wexler LH; Kramer K; Spasojevic I; Dunkel IJ
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine.
    Sun W; Modak S
    Onco Targets Ther; 2012; 5():21-9. PubMed ID: 22419878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism.
    Chiarini F; Del Sole M; Mongiorgi S; Gaboardi GC; Cappellini A; Mantovani I; Follo MY; McCubrey JA; Martelli AM
    Leukemia; 2008 Jun; 22(6):1106-16. PubMed ID: 18385752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.
    Friedman DR; Lanasa MC; Davis PH; Allgood SD; Matta KM; Brander DM; Chen Y; Davis ED; Volkheimer AD; Moore JO; Gockerman JP; Sportelli P; Weinberg JB
    Leuk Lymphoma; 2014 May; 55(5):1067-75. PubMed ID: 23863122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
    Chee KG; Longmate J; Quinn DI; Chatta G; Pinski J; Twardowski P; Pan CX; Cambio A; Evans CP; Gandara DR; Lara PN
    Clin Genitourin Cancer; 2007 Dec; 5(7):433-7. PubMed ID: 18272025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
    Guidetti A; Carlo-Stella C; Locatelli SL; Malorni W; Mortarini R; Viviani S; Russo D; Marchianò A; Sorasio R; Dodero A; Farina L; Giordano L; Di Nicola M; Anichini A; Corradini P; Gianni AM
    Clin Cancer Res; 2014 Nov; 20(22):5641-51. PubMed ID: 25239609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perifosine--a new option in treatment of acute myeloid leukemia?
    Krawczyk J; Keane N; Swords R; O'Dwyer M; Freeman CL; Giles FJ
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1315-27. PubMed ID: 23931614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo.
    Segerström L; Baryawno N; Sveinbjörnsson B; Wickström M; Elfman L; Kogner P; Johnsen JI
    Int J Cancer; 2011 Dec; 129(12):2958-65. PubMed ID: 21717457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.